Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 5/20 | 0.48 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.48 |
| ▸ | F11 | P03951 | 15/20 | 0.46 |
| ▸ | KLKB1 | P03952 | 14/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14692448 | 0.87 | NOTUM (0.55) | RXRAGRIN1GRIN2BF11KLKB1 | |
| SCHEMBL18945325 | 0.85 | RXRA (0.48) | RXRAGRIN1GRIN2BF11KLKB1 | |
| SCHEMBL14706222 | 0.85 | RXRA (0.46) | RXRAGRIN1GRIN2BF11KLKB1 | |
| SCHEMBL17365300 | 0.84 | RXRA (0.48) | RXRAGRIN1GRIN2B | |
| SCHEMBL20263291 | 0.80 | NOTUM (0.55) | — | |
| SCHEMBL30280499 | 0.80 | NOTUM (0.55) | — | |
| SCHEMBL15933197 | 0.78 | KMT2A (0.44) | KLKB1 | |
| SCHEMBL15933311 | 0.75 | NOTUM (0.42) | F11KLKB1 | |
| SCHEMBL15933196 | 0.75 | NOTUM (0.42) | RXRAGRIN1GRIN2BF11KLKB1 | |
| SCHEMBL15933255 | 0.75 | NOTUM (0.45) | RXRAGRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9902742-B2 | Macrocycles as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-02-27 | — | — | US | disclosed |
| US-20170158712-A1 | NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-06-08 | — | — | US | disclosed |
| EP-2739628-B1 | NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-06-07 | — | — | EP | disclosed |
| US-9611274-B2 | Macrocycles as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-04-04 | — | — | US | disclosed |
| US-20160068544-A1 | NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-03-10 | — | — | US | disclosed |
| US-9221818-B2 | Macrocycles as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-29 | — | — | US | disclosed |
| US-20140221338-A1 | NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160068544-A1 | NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F12 | RXRA 4487/4885GRIN1 3839/4885GRIN2B 3964/4885 |
| US-20140221338-A1 | NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F12 | RXRA 4487/4885GRIN1 3839/4885GRIN2B 3964/4885 |
| US-20170158712-A1 | NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F12 | RXRA 4487/4885GRIN1 3839/4885GRIN2B 3964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.